Sitagliptin phosphate monohydrate (CAS: 654671-77-9)

Acid west his dean was first developed by Merck, Germany won the U.S. food and drug administration approved for the treatment of type 2 diabetes dipeptide base peptidase Ⅳ (DDP – 4) inhibitor medicine, is a new type of diabetes, can increase the body’s own ability to reduce high blood sugar levels, inhibit the enzyme activity and relatively improve shortness of naturally occurring intestinal insulin, including sample glucagon peptide 1 promote insulin and glucose dependence peptide levels, increased insulin production is triggering the pancreas and the liver to stop glucose production, and finally the clinical effect of lowering blood sugar concentration. The characteristic of this product is in stimulating insulin secretion, at the same time can reduce hungry feeling, and will not put on weight, also won’t hypoglycemia and edema occur, suitable for diabetic patients with poor blood sugar control and frequent hypoglycemia. 552 cases of clinically mild-to-moderate patients with type 2 diabetes, take a daily phosphate west he listed, take 100 milligrams, 12 weeks after can reduce glycated hemoglobin 0.6% – 0.6%

Pharmacodynamics

This drug for dipeptide peptidase 4 (DPP – 4) depressants, by protecting endogenous im fall blood sugar, and enhance its role and control blood sugar levels. Glucose dependence on promoting insulin releasing peptide (GIP) and glucagon peptide 1 (glp-1), as for dietary intake and release of intestinal fall blood sugar. Glp-1 and GIP can increase insulin synthesis and through intracellular signaling pathways from the release of the islet beta cells, glp-1 can reduce islet alpha cells glucagon secretion, reduce hepatic glucose production. But glp-1 and GIP vetted by DPP – 4 quick metabolism, leading to loss of its effect on promoting insulin. This drug inhibits the degradation of im fall blood sugar, the DPP – 4, so it can enhance the function of glp-1 and GIP, increase insulin release and reduce the cycle of glucagon levels (this role in glucose dependencies). This drug is selective inhibition of DPP – 4, the DPP – 8 or DPP – 9 no inhibitory activity. 2. The pharmacokinetic This drug is 1-4 hours after oral reach peak blood drug concentrations of 950 nmol, area under the curve tendency for 8.52 h, absolute bioavailability of about 87%, and protein

Application:To lift the body’s own’s ability to reduce high blood sugar level.